Copyright Reports & Markets. All rights reserved.

Global Duchenne Muscular Dystrophy Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Duchenne Muscular Dystrophy Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Duchenne Muscular Dystrophy Consumption 2014-2024
        • 2.1.2 Duchenne Muscular Dystrophy Consumption CAGR by Region
      • 2.2 Duchenne Muscular Dystrophy Segment by Type
        • 2.2.1 Deflazacort
        • 2.2.2 Prednisone
        • 2.2.3 Others
      • 2.3 Duchenne Muscular Dystrophy Consumption by Type
        • 2.3.1 Global Duchenne Muscular Dystrophy Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2014-2019)
      • 2.4 Duchenne Muscular Dystrophy Segment by Application
        • 2.4.1 Male
        • 2.4.2 Female
      • 2.5 Duchenne Muscular Dystrophy Consumption by Application
        • 2.5.1 Global Duchenne Muscular Dystrophy Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Duchenne Muscular Dystrophy Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Duchenne Muscular Dystrophy Sale Price by Application (2014-2019)

      3 Global Duchenne Muscular Dystrophy by Players

      • 3.1 Global Duchenne Muscular Dystrophy Sales Market Share by Players
        • 3.1.1 Global Duchenne Muscular Dystrophy Sales by Players (2017-2019)
        • 3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Players (2017-2019)
      • 3.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Players
        • 3.2.1 Global Duchenne Muscular Dystrophy Revenue by Players (2017-2019)
        • 3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Players (2017-2019)
      • 3.3 Global Duchenne Muscular Dystrophy Sale Price by Players
      • 3.4 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Duchenne Muscular Dystrophy Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Duchenne Muscular Dystrophy by Regions

      • 4.1 Duchenne Muscular Dystrophy by Regions
        • 4.1.1 Global Duchenne Muscular Dystrophy Consumption by Regions
        • 4.1.2 Global Duchenne Muscular Dystrophy Value by Regions
      • 4.2 Americas Duchenne Muscular Dystrophy Consumption Growth
      • 4.3 APAC Duchenne Muscular Dystrophy Consumption Growth
      • 4.4 Europe Duchenne Muscular Dystrophy Consumption Growth
      • 4.5 Middle East & Africa Duchenne Muscular Dystrophy Consumption Growth

      5 Americas

      • 5.1 Americas Duchenne Muscular Dystrophy Consumption by Countries
        • 5.1.1 Americas Duchenne Muscular Dystrophy Consumption by Countries (2014-2019)
        • 5.1.2 Americas Duchenne Muscular Dystrophy Value by Countries (2014-2019)
      • 5.2 Americas Duchenne Muscular Dystrophy Consumption by Type
      • 5.3 Americas Duchenne Muscular Dystrophy Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Duchenne Muscular Dystrophy Consumption by Countries
        • 6.1.1 APAC Duchenne Muscular Dystrophy Consumption by Countries (2014-2019)
        • 6.1.2 APAC Duchenne Muscular Dystrophy Value by Countries (2014-2019)
      • 6.2 APAC Duchenne Muscular Dystrophy Consumption by Type
      • 6.3 APAC Duchenne Muscular Dystrophy Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Duchenne Muscular Dystrophy by Countries
        • 7.1.1 Europe Duchenne Muscular Dystrophy Consumption by Countries (2014-2019)
        • 7.1.2 Europe Duchenne Muscular Dystrophy Value by Countries (2014-2019)
      • 7.2 Europe Duchenne Muscular Dystrophy Consumption by Type
      • 7.3 Europe Duchenne Muscular Dystrophy Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Duchenne Muscular Dystrophy by Countries
        • 8.1.1 Middle East & Africa Duchenne Muscular Dystrophy Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Duchenne Muscular Dystrophy Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Duchenne Muscular Dystrophy Consumption by Type
      • 8.3 Middle East & Africa Duchenne Muscular Dystrophy Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Duchenne Muscular Dystrophy Distributors
      • 10.3 Duchenne Muscular Dystrophy Customer

      11 Global Duchenne Muscular Dystrophy Market Forecast

      • 11.1 Global Duchenne Muscular Dystrophy Consumption Forecast (2019-2024)
      • 11.2 Global Duchenne Muscular Dystrophy Forecast by Regions
        • 11.2.1 Global Duchenne Muscular Dystrophy Forecast by Regions (2019-2024)
        • 11.2.2 Global Duchenne Muscular Dystrophy Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Duchenne Muscular Dystrophy Forecast by Type
      • 11.8 Global Duchenne Muscular Dystrophy Forecast by Application

      12 Key Players Analysis

      • 12.1 PTC Therapeutics
        • 12.1.1 Company Details
        • 12.1.2 Duchenne Muscular Dystrophy Product Offered
        • 12.1.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 PTC Therapeutics News
      • 12.2 Sarepta Therapeutics
        • 12.2.1 Company Details
        • 12.2.2 Duchenne Muscular Dystrophy Product Offered
        • 12.2.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Sarepta Therapeutics News
      • 12.3 Others
        • 12.3.1 Company Details
        • 12.3.2 Duchenne Muscular Dystrophy Product Offered
        • 12.3.3 Others Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Others News

      ...

        13 Research Findings and Conclusion

        uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
        The classification of duchenne muscular dystrophy includes deflazacort, prednisone and others. And the proportion of deflazacort in 2017 is about 44%.
        Duchenne muscular dystrophy is widely used by Male patients and Female patients. The most proportion of duchenne muscular dystrophy sold to Male patients, and the proportion in 2017 is about 81%.

        According to this study, over the next five years the Duchenne Muscular Dystrophy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Duchenne Muscular Dystrophy business, shared in Chapter 3.

        This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy market by product type, application, key manufacturers and key regions and countries.

        This study considers the Duchenne Muscular Dystrophy value and volume generated from the sales of the following segments:

        Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
        Deflazacort
        Prednisone
        Others
        Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
        Male
        Female

        This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
        Americas
        United States
        Canada
        Mexico
        Brazil
        APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
        Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
        Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

        The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
        PTC Therapeutics
        Sarepta Therapeutics
        Others
        ...

        In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

        Research objectives
        To study and analyze the global Duchenne Muscular Dystrophy consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
        To understand the structure of Duchenne Muscular Dystrophy market by identifying its various subsegments.
        Focuses on the key global Duchenne Muscular Dystrophy manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
        To analyze the Duchenne Muscular Dystrophy with respect to individual growth trends, future prospects, and their contribution to the total market.
        To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
        To project the consumption of Duchenne Muscular Dystrophy submarkets, with respect to key regions (along with their respective key countries).
        To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
        To strategically profile the key players and comprehensively analyze their growth strategies.

        Buy now